In 20,568 women with BC who underwent GGT, Kurian et al. found that women with PGVs in BC predisposition genes were more likely to overuse BLM and chemotherapy and to underuse RT compared with patients with negative results.35 While our study found that patients with PGVs in BRCA1 and BRCA2 were at increased odds for undergoing BLM compared with those with negative results, patients with PGVs in non-BRCA genes were not significantly more likely to undergo BLM or to omit RT. This evidence concerns the gene BRCA2 and breast cancer.